Division of Gastroenterology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Division of Gastroenterology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; "Motts" Tonelli Esophageal Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Gastroenterology. 2012 Sep;143(3):576-581. doi: 10.1053/j.gastro.2012.05.005. Epub 2012 May 15.
BACKGROUND & AIMS: Radiofrequency ablation (RFA) is a safe alternative to esophagectomy for patients with dysplastic Barrett's esophagus (BE). Although some studies have indicated that RFA is effective at eradicating dysplasia, most have found that RFA is not as effective in eradicating intestinal metaplasia. We investigated whether uncontrolled reflux is associated with persistent intestinal metaplasia after RFA.
Thirty-seven patients with BE underwent RFA, high-resolution manometry, and 24-hour impedance-pH testing; they received proton pump inhibitors twice daily. Patients returned every 2 months for repeat treatment or standard surveillance. Patients were classified as complete responders (CRs) if all intestinal metaplasia was eradicated in fewer than 3 ablation sessions. We analyzed clinical parameters to identify factors associated with a CR or incomplete responder (ICR).
Among the 37 patients, 22 had a CR and 15 had an ICR. Mann-Whitney U tests revealed that length of BE, size of hiatal hernia, and frequency of reflux, but not acid reflux, differed between CRs and ICRs. CRs had fewer weakly acidic events than ICRs (29.5 vs 52; P < .05) and total reflux events (33.5 vs 60; P < .05), and a trend toward fewer weakly alkaline events (1.0 vs 5.0; P = .06). No other clinical or manometric features differed between groups.
Uncontrolled, predominantly weakly acidic reflux despite twice-daily proton pump inhibitor therapy before RFA increases the incidence of persistent intestinal metaplasia after ablation in patients with BE. Length of BE and size of hiatal hernia also were associated with persistent intestinal metaplasia after RFA.
射频消融(RFA)是治疗异型增生性 Barrett 食管(BE)患者的一种安全替代手术方法。虽然一些研究表明 RFA 能有效消除异型增生,但大多数研究发现 RFA 对消除肠化生的效果并不理想。我们研究了在 RFA 后,未控制的反流是否与肠化生持续存在有关。
37 例 BE 患者接受 RFA、高分辨率测压和 24 小时阻抗-pH 检测;他们每天接受两次质子泵抑制剂治疗。患者每 2 个月返回进行重复治疗或标准监测。如果在少于 3 次消融治疗中所有肠化生均被消除,则患者被归类为完全应答者(CR)。我们分析了临床参数,以确定与 CR 或不完全应答者(ICR)相关的因素。
在 37 例患者中,22 例为 CR,15 例为 ICR。Mann-Whitney U 检验显示,CR 和 ICR 之间 BE 长度、食管裂孔疝大小和反流频率(而非酸反流)存在差异。CR 的弱酸性事件少于 ICR(29.5 比 52;P <.05)和总反流事件(33.5 比 60;P <.05),弱碱性事件也有减少趋势(1.0 比 5.0;P =.06)。两组间其他临床或测压特征无差异。
尽管在 RFA 前每天接受两次质子泵抑制剂治疗,但仍存在未控制的、主要为弱酸性反流,这会增加 BE 患者消融后肠化生持续存在的发生率。BE 长度和食管裂孔疝大小也与 RFA 后肠化生持续存在有关。